BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29605575)

  • 21. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
    Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
    Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
    Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
    Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia.
    Socha P; Zduńczyk S; Tobolski D; Janowski T
    Pol J Vet Sci; 2018 Dec; 21(4):559-566. PubMed ID: 30605276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative bidimentional and Doppler ultrasound assessment of the effect of a GnRH antagonist on canine prostatic hyperplasia.
    D'Francisco F; Merlo ML; Lapuente C; Blasco A; Gobello C
    Theriogenology; 2020 Mar; 144():41-44. PubMed ID: 31901534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.
    Montironi R; Valli M; Fabris G
    J Clin Pathol; 1996 Apr; 49(4):324-8. PubMed ID: 8655710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
    Peters DH; Sorkin EM
    Drugs; 1993 Jul; 46(1):177-208. PubMed ID: 7691505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
    CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
    Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
    Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
    Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
    Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs.
    Dearakhshandeh N; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Abbaszadeh Hasiri M; Golchin-Rad K
    Theriogenology; 2020 Jan; 142():236-245. PubMed ID: 31711694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis.
    Yin T; Qiao Z; Li Y; Li D; Jiang M; An C; Wang F; Zuo M; Hu K; Li Q
    Am J Ther; 2017; 24(5):e517-e523. PubMed ID: 26322675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.
    Leoci R; Aiudi G; Silvestre F; Lissner E; Lacalandra GM
    Prostate; 2014 Aug; 74(11):1132-41. PubMed ID: 24913937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?
    Angrimani DSR; Bicudo LC; Llamas Luceño N; Rui BR; Silva MF; Losano JDA; Leemans B; Van Soom A; Vannucchi CI
    Basic Clin Androl; 2020; 30():9. PubMed ID: 32695403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Conservative treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2008 Oct; 149(40):1875-80. PubMed ID: 18815106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.
    Tewari A; Shinohara K; Narayan P
    Urology; 1995 Feb; 45(2):258-64; discussion 265. PubMed ID: 7531900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland.
    Ząbkowski T
    Pharmacol Rep; 2014 Aug; 66(4):565-9. PubMed ID: 24948055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
    Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
    Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.